Sign up today to learn more about Humacyte stock
EquityZen is a marketplace for shares of proven pre IPO tech companies
Humacyte Stock
Regenerative Medical Technology Company
About Humacyte Stock
Humacyte, Inc. develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products called human acellular vessels (HAV) for regenerative medicine and vascular surgery applications. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.
Investors
Access Industries
Gett, WeLab, IronSource, Deezer, Humacyte, TangoMe, Selina, Sentient Technologies, DigitalOcean
Bangkok bank
California Institute for Regenerative Medicine
Pacific Eagle Asset Management
Funding History
| January 2015 | $74.1M |
|---|---|
| October 2015 | $136M |
| March 2018 | $75.0M |
| June 2018 | $150M |
Management
Chief Executive Officer
Jeffrey Lawson
Chief Financial Officer
Douglas Blankenship
Press
Business Wire - Mar, 27 2020
Business Wire - Mar, 2 2020
Business Wire - Apr, 8 2019
xconomy - Mar, 8 2019
xconomy - Jun, 25 2018
prnewswire - Jun, 11 2018
businesswire - Mar, 9 2018
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Humacyte or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
